Published in AIDS Weekly, August 21st, 2006
Driving this increase was revenue from the company's HIV testing products, which grew 16% to $12.8 million in the second quarter of 2006 compared to $11 million for the same period in 2005.
For the second quarter of 2006, a net loss of $21.8 million, or 17 cents per common share, was recorded, compared to a net profit of $700,000, or 1 cent per common share, for the same period in 2005. Included in these...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.